GlassScriptPhysician profile
Tyrus M White
NPI 1124281167
$11,643.49
in general payments reported to CMS, 2019-2025
66 companies · $2,901 in 2025
The $2,901 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,717 · 2020: $857 · 2021: $692 · 2022: $218 · 2023: $2,342 · 2024: $2,918 · 2025: $2,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,138 · Education: $21.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,138.25 |
| Education | $21.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $956.84 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $887.28 | 2019-2025 | Tagrisso, Enhertu, Calquence |
| Janssen Biotech, INC. | $725.45 | 2019-2025 | Darzalex, Tecvayli, Imbruvica |
| Novartis Pharmaceuticals Corporation | $717.03 | 2019-2025 | |
| Amgen INC. | $618.77 | 2019-2023 | Lumakras, Blincyto |
| Pfizer INC. | $560.93 | 2019-2025 | |
| Daiichi Sankyo INC. | $421.17 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Celgene Corporation | $365.14 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Regeneron Healthcare Solutions, INC. | $355.32 | 2019-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $347.64 | 2019-2024 | Opdualag, Opdivo |
| Genzyme Corporation | $330.57 | 2019-2025 | |
| Incyte Corporation | $313.56 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Astellas Pharma US INC | $288.18 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Gilead Sciences, INC. | $262.28 | 2023-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $247.47 | 2019-2025 | Fruzaqla, Iclusig, Ninlaro |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $245.58 | 2020-2025 | Venclexta |
| Seagen INC. | $240.78 | 2019-2023 | Adcetris, Padcev, Tukysa |
| Genentech USA, INC. | $222.95 | 2019-2024 | Venclexta, Polivy, Tecentriq |
| Exelixis INC. | $205.12 | 2019-2022 | |
| Genmab U.S., INC. | $193.51 | 2023-2025 | Tivdak, Epkinly |
| Jazz Pharmaceuticals INC. | $187.85 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $182.20 | 2019-2023 | Imbruvica, Epkinly |
| Emd Serono, INC. | $177.98 | 2023-2025 | Bavencio |
| Aveo Pharmaceuticals, INC. | $132.20 | 2023-2025 | Fotivda |
| Lilly USA, LLC | $125.53 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Foundation Medicine, INC. | $124.87 | 2019-2020 | |
| Dova Pharmaceuticals | $118.20 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.31 | 2019-2025 | |
| Cumberland Pharmaceuticals, INC. | $109.32 | 2023-2024 | Sancuso |
| Ipsen Biopharmaceuticals, INC | $104.48 | 2023-2025 | Onivyde, Tazverik |
| Glaxosmithkline, LLC. | $99.31 | 2020-2025 | Ojjaara |
| Karyopharm Therapeutics INC. | $92.85 | 2020-2025 | Xpovio |
| Pharmacosmos Therapeutics INC. | $89.70 | 2021-2025 | Monoferric |
| Novo Nordisk INC | $88.47 | 2019 | |
| Rigel Pharmaceuticals, INC. | $87.52 | 2019-2024 | Rezlidhia, Tavalisse |
| Array Biopharma INC | $85.09 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Eisai INC. | $85.04 | 2019-2025 | |
| Pharmaessentia USA Corporation | $79.93 | 2023-2025 | Besremi |
| Coherus Oncology, INC. | $73.14 | 2020-2024 | |
| Tesaro, INC. | $69.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.95 | 2020-2023 | Gilotrif |
| Blueprint Medicines Corporation | $58.11 | 2023-2025 | Ayvakit |
| Amag Pharmaceuticals, INC. | $56.09 | 2019-2020 | |
| Puma Biotechnology, INC. | $54.00 | 2024-2025 | |
| Clovis Oncology, INC. | $53.28 | 2019-2020 | |
| Taiho Oncology, INC. | $48.60 | 2024-2025 | |
| Beone Medicines USA, INC. | $46.95 | 2025 | Tevimbra, Brukinsa |
| Sun Pharmaceutical Industries INC. | $39.86 | 2023-2024 | Yonsa, Odomzo |
| Verastem, INC. | $37.92 | 2019 | |
| Iovance Biotherapeutics, INC. | $37.90 | 2025 | Amtagvi |
| Adc Therapeutics America, INC. | $36.96 | 2023 | |
| Stemline Therapeutics INC. | $36.64 | 2025 | Orserdu |
| Kyowa Kirin, INC. | $36.04 | 2021 | |
| Alexion Pharmaceuticals, INC. | $35.54 | 2019-2023 | Ultomiris |
| Beigene USA, INC. | $35.06 | 2024 | Brukinsa |
| Tempus Ai, INC | $29.14 | 2024 | Xt Cdx |
| Kite Pharma, INC. | $26.55 | 2021 | |
| Advanced Accelerator Applications | $25.75 | 2019-2020 | |
| Tosoh Bioscience, INC. | $25.00 | 2019 | |
| Celltrion USA INC. | $24.47 | 2025 | Vegzelma |
| Progenics Pharmaceuticals, INC. | $23.21 | 2024 | |
| Sobi, INC | $21.77 | 2024 | |
| Caris Mpi, INC. | $17.56 | 2025 | Mi Cancer Seek |
| Sanofi-Aventis U.S. LLC | $14.08 | 2021 | |
| Springworks Therapeutics, INC. | $13.54 | 2024 | Ogsiveo |
| Tactile Systems Technology INC | $12.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyrus White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.